Research Roundup

Debbie Rigby rounds up the latest in research news

Thunderstorm-triggered asthma: what we know so far

Thunderstorm-triggered asthma (TA) is the occurrence of acute asthma attacks immediately following a thunderstorm. TA in the 2016 event in Melbourne was associated with allergic rhinitis, ryegrass pollen sensitization, pre-existing asthma, poor adherence to inhaled corticosteroid preventer therapy, hospital admission for asthma in the previous year and outdoor location at the time of the storm. Patients without a prior history of asthma were also affected.

Journal of Asthma and Allergy 2019;12:101–108.


Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease

Compared with placebo, once‐daily LABA/LAMA (either IND/GLY, UMEC/VI or TIO/OLO) via a combination inhaler is associated with a clinically significant improvement in lung function and health‐related quality of life in patients with mild‐to‐moderate COPD; UMEC/VI appears to reduce the rate of exacerbations in this population. These conclusions are supported by moderate or high certainty evidence based on studies with an observation period of up to one year.

Cochrane Database of Systematic Reviews 2019, Issue 3.


Rivaroxaban in atrial fibrillation cardioversion

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a prevalence of about 2–3% in the general population, representing a powerful risk factor for stroke and systemic thromboembolism and increased mortality and morbidity. This report provides an overview of the main randomized controlled trial and the main real-life studies, documenting the use of rivaroxaban in patients with non-valvular AF who underwent the cardioversion procedure.

Therapeutics and Clinical Risk Management 2019:15 613–626.


Twenty-Four-Hour Blood Pressure–Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension

The risk of cardiovascular disease and mortality in salt-sensitive patients with diabetes mellitus and uncontrolled nocturnal hypertension is high. Empagliflozin 10 mg once daily significantly reduced nighttime systolic blood pressure without marked reductions in glucose when added to existing antihypertensive and antidiabetic therapy.

Circulation. 2019;139:2089–2097.

Previous Staying the same
Next Service recognised

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply